Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

15.10 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co.

< Previous 1 2 3 4 5 6 Next >
Looking Into Organon's Recent Short Interest
Via Benzinga
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
These dividend stocks all pay yields of around 6% and higher. 
Via The Motley Fool
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade. 
Via Benzinga
P/E Ratio Insights for Organon
Via Benzinga
3 Cheap High Dividend Stocks For Passive Income
These undervalued high yield stocks could return over 10% per year. 
Via Talk Markets
High Dividend 50: Organon & Co.
Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%. 
Via Talk Markets
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and... 
Via Talk Markets
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2... 
Via Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks." 
Via Benzinga
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
These exchange-traded funds should keep the income flowing in regularly. 
Via The Motley Fool
Topics ETFs
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence. 
Via InvestorPlace
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
Organon Beats On Q1, Women's Health Leads the Charge
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared. 
Via Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing. 
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. 
Via InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals. 
Via InvestorPlace
5 Value Stocks In The Healthcare Sector
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. 
Via Investor's Business Daily
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion. 
Via InvestorPlace
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast).  
Via Benzinga
Exposures Product Safety
Don't Overlook These Low-Risk High-Dividend Yielding Stocks
Given the rally in the S&P 500 and the Nasdaq over the last year, it may be wise to consider stocks that should be less volatile during market corrections. Even better is when stocks have dividend... 
Via Talk Markets
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.